Quarterly ResultJun 29, 2026, 04:57 PM
Elite Pharmaceuticals FY26 Revenue $148.9M (+77%); Income $49.1M (+151%)
AI Summary
Elite Pharmaceuticals reported strong financial results for the fiscal year ended March 31, 2026, with consolidated revenues reaching $148.9 million, a 77% increase year-over-year. Income from operations surged by 151% to $49.1 million, driven by new product launches including Lisdexamfetamine, Oxycodone Acetaminophen, Naltrexone, and Phentermine. The company will host a conference call on June 30, 2026, to discuss these results and provide a business update.
Key Highlights
- Consolidated revenues for Fiscal 2026 reached $148.9 million.
- Revenues increased by $64.8 million or approximately 77% year-over-year.
- Income from operations was $49.1 million for Fiscal 2026.
- Income from operations increased by $29.5 million or approximately 151% year-over-year.
- Growth was primarily driven by Lisdexamfetamine, Oxycodone Acetaminophen, Naltrexone, and Phentermine launches.
- Elite Pharmaceuticals will host a conference call on June 30, 2026, at 11:30 AM EDT.
- The conference call will provide a general business update and address stockholder questions.
Price Impact
More from ELTP